Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 24 2023 - 2:01AM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced that the European Society of Gene &
Cell Therapy (ESGCT) has accepted six Sangamo abstracts for
presentation at the 30th Annual Congress being held October 24-27,
2023, in-person in Brussels, Belgium. Presentations will focus on
the progression of Sangamo’s pre-clinical programs, including data
from its neurology epigenetic regulation programs, and advancements
in the CAR-Treg pipeline.
“The data we are presenting at ESGCT reflect the important
advances being made across our neurology and CAR-Treg pipelines,”
said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo.
“We are excited to showcase these innovations, which reinforce the
potential of our science to create transformative treatments for
patients suffering with serious diseases.”
Data to be presented at the ESGCT Annual Congress include an
oral presentation demonstrating how zinc finger activators (ZF-As)
may be designed to potentially address neurodevelopmental disorders
such as autism spectrum disorder and intellectual disability, for
which limited therapeutic treatments currently exist. This
presentation will show how ZF-As can be designed to restore normal
gene and protein expression of SCN2A in vitro and in vivo. This
will be accompanied by a poster presentation demonstrating Shank3
gene activation, mediated by ZF-As as a potential therapeutic
approach for Phelan-McDermid syndrome. Both datasets originate from
pre-clinical programs previously co-developed in partnership with
Novartis.
Additional presentations at the ESGCT Annual Congress will
unveil for the first time pre-clinical data showing that autologous
MOG-CAR-Tregs may provide a long-lasting treatment option to
potentially address the underlying cause of multiple sclerosis, as
well as updated pre-clinical data evaluating IL23R-CAR-Tregs as a
potentially effective treatment option to address inflammation for
patients with Crohn’s disease. Data will also showcase our platform
capability of efficient and durable epigenetic cell engineering
using compact ZF-Repressors to target immune checkpoints with the
potential to improve the anti-tumor activity of T cells in cancer
therapy.
ESGCT Annual Congress Presentations and
Invited Sessions
Epigenetic Regulation for
Neurology:
- Zinc Finger Activators restore normal gene and protein
expression in a mouse model of SCN2A haploinsufficiency
- Abstract No. OR09
- Oral Presentation – October 24; 17:00-19:00
- Shank3 Gene Activation Mediated by Zinc Finger Activators
(ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
- Abstract No. P415
- Poster Presentation – October 25; 17:00 to 18:15 and October
26; 20:30 to 21:30
Cell Therapy Regulatory T-Cells (CAR-Tregs)
- Myelin Oligodendrocyte Glycoprotein (MOG)-CAR-Tregs – A novel
approach to treat multiple sclerosis
- Abstract No. P475
- Poster Presentation – October 25; 17:00 to 18:15 and October
26; 20:30 to 21:30
- Evaluation of IL23R as a target for CAR-Tregs at the site of
inflammation in subjects with Crohn’s Disease
- Abstract No. P487
- Poster Presentation – October 25; 17:00 to 18:15 and October
26; 20:30 to 21:30
- Multimerization of Chimeric Antigen Receptor (CAR) binding
domains: A solution to assess tissue specificity of low to medium
affinity scFv
- Abstract No. P503
- Poster Presentation – October 25; 17:00 to 18:15 and October
26; 20:30 to 21:30
CAR-T in Oncology
- Multiplex targeting of immune checkpoints with compact zinc
finger repressors to improve anti-tumor activity of T cells
- Abstract No. P212
- Poster Presentation – October 25; 18:15 to 19:30 and October
26; 19:30 to 20:30
All ESGCT presentations are available on the Sangamo
website.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical
company with a robust genomic medicines pipeline. Using
ground-breaking science, including our proprietary zinc finger
genome engineering technology and manufacturing expertise, Sangamo
aims to create new genomic medicines for patients suffering from
diseases for which existing treatment options are inadequate or
currently don’t exist. To learn more, visit and connect with us on
LinkedIn and Twitter.
Sangamo Forward Looking Statements
This press release contains forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to Sangamo’s
technologies, the presentation of data from various therapeutic and
research programs and the potential of these programs to
demonstrate therapeutic benefit and transform the lives of
patients. These statements are not guarantees of future performance
and are subject to certain risks and uncertainties that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the research development
process, including the results of clinical trials; the regulatory
approval process for product candidates; and the potential for
technological developments that obviate technologies used by
Sangamo. Actual results may differ from those projected in
forward-looking statements due to risks and uncertainties that
exist in Sangamo's operations and business. These risks and
uncertainties are described more fully in our Securities and
Exchange Commission filings and reports, including in our Annual
Report on Form 10-K for the year ended December 31, 2022.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231023250843/en/
Investor Relations & Media Inquiries Louise Wilkie
ir@sangamo.com media@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024